Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
VRT-106 by Guangzhou Virotech Pharmaceutical for Metastatic Prostate Cancer: Likelihood of Approval
VRT-106 is under clinical development by Guangzhou Virotech Pharmaceutical and currently in Phase I for Metastatic Prostate Cancer. According to...
VRT-106 by Guangzhou Virotech Pharmaceutical for Metastatic Melanoma: Likelihood of Approval
VRT-106 is under clinical development by Guangzhou Virotech Pharmaceutical and currently in Phase I for Metastatic Melanoma. According to GlobalData,...
VRT-106 by Guangzhou Virotech Pharmaceutical for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
VRT-106 is under clinical development by Guangzhou Virotech Pharmaceutical and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According...
VRT-106 by Guangzhou Virotech Pharmaceutical for Cervical Cancer: Likelihood of Approval
VRT-106 is under clinical development by Guangzhou Virotech Pharmaceutical and currently in Phase I for Cervical Cancer. According to GlobalData,...
VRT-106 by Guangzhou Virotech Pharmaceutical for Solid Tumor: Likelihood of Approval
VRT-106 is under clinical development by Guangzhou Virotech Pharmaceutical and currently in Phase I for Solid Tumor. According to GlobalData,...